Dr. Janice M. Mehnert on Immunotherapy vs BRAF/MEK Inhibitors in the Adjuvant Setting for Melanoma

Leggi l'articolo originale


Cancer Network spoke with Janice M. Mehnert, MD, of Rutgers Cancer Institute, about the use of immunotherapy vs BRAF/MEK inhibitors in the adjuvant setting for melanoma.

Lascia un commento